0001062993-24-003202.txt : 20240214
0001062993-24-003202.hdr.sgml : 20240214
20240214184324
ACCESSION NUMBER: 0001062993-24-003202
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240212
FILED AS OF DATE: 20240214
DATE AS OF CHANGE: 20240214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dorling Janet
CENTRAL INDEX KEY: 0001738144
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36500
FILM NUMBER: 24641321
MAIL ADDRESS:
STREET 1: C/O ACHAOGEN, INC.
STREET 2: 1 TOWER PLACE, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CymaBay Therapeutics, Inc.
CENTRAL INDEX KEY: 0001042074
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 943103561
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7575 GATEWAY BOULEVARD
STREET 2: SUITE 110
CITY: NEWARK
STATE: CA
ZIP: 94560
BUSINESS PHONE: 510-293-8800
MAIL ADDRESS:
STREET 1: 7575 GATEWAY BOULEVARD
STREET 2: SUITE 110
CITY: NEWARK
STATE: CA
ZIP: 94560
FORMER COMPANY:
FORMER CONFORMED NAME: METABOLEX, INC.
DATE OF NAME CHANGE: 20090721
FORMER COMPANY:
FORMER CONFORMED NAME: METABOLEX INC
DATE OF NAME CHANGE: 19970710
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0508
4
2024-02-12
0001042074
CymaBay Therapeutics, Inc.
CBAY
0001738144
Dorling Janet
C/O CYMABAY THERAPEUTICS, INC.
7575 GATEWAY BLVD., SUITE 110
NEWARK
CA
94560
1
0
0
0
1
Common Stock
2024-02-12
4
M
0
6000
4.63
A
6000
D
Common Stock
2024-02-12
4
S
0
6000
31.9748
D
0
D
Employee Stock Option (right to buy)
4.63
2024-02-12
4
M
0
6000
0
D
2031-04-04
Common Stock
6000
55000
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on August 9, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.93 to $32.00, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option grant vests as to 1/36 of the underlying shares monthly from April 5, 2021.
/s/ Paul Quinlan, as attorney-in-fact for Janet Dorling
2024-02-14